Bicycle Therapeutics slides on $125 mln share offering
** Drug developer's shares BCYC.O drop as much as 3% to
$52
** Co commences offering of American Depositary Shares (ADS)
worth $125 mln urn:newsml:reuters.com:*:nBwb0f4p2a
** Each ADS represents one ordinary share, co says
** BCYC plans to use proceeds from offering to fund future
products and research and development
** Goldman Sachs & Co, Morgan Stanley and SVB Leerink are
the underwriters
(Reporting by Niket Nishant in Bengaluru)
((Niket.Nishant@thomsonreuters.com;))
Recent news on Bicycle Therapeutics
See all newsBicycle Therapeutics PLC reports results for the quarter ended September 30 - Earnings Summary
UK's Bicycle Therapeutics Q3 loss narrows as expenses fall
Bicycle Therapeutics PLC expected to post a loss of 43 cents a share - Earnings Preview
UK's Bicycle Therapeutics Q2 net loss narrows on reduced clinical program expenses
Bicycle Therapeutics Q1 revenue drops after partnership terminations